Co-Diagnostics

Co-Diagnostics is an American pharmaceutical company specializing in molecular diagnostics. It develops, manufactures and sells reagents used for diagnostic tests that function through the detection and analysis of nucleic acid molecules. Co-Diagnostics also offers diagnostic equipment from other manufacturers in the form of autonomous laboratory systems. The headquarters are located in Salt Lake City, Utah, USA.
Co-Diagnostics stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Co-Diagnostics balance sheet

Report period2018 2019 2020 2021 2022 Q3 23
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Co-Diagnostics cash flows

Report period2018 2019 2020 2021 2022 Q3 23 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Adjusted EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Co-Diagnostics multipliers

Report period2018 2019 2020 2021 2022 Q3 23 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
Net Debt/EBITDA adj.
EV/EBITDA
EV/EBITDA adj.

Co-Diagnostics profitability

Report period2018 2019 2020 2021 2022 Q3 23 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Co-Diagnostics assets
Co-Diagnostics cash flows

Co-Diagnostics shares

TickerNameTypeNominal valueISINPrice
CODX:USCo-Diagnostics, Inc.Common share-US1897631057$1.18
Co-Diagnostics news
13.05.2022
Co-Diagnostics' GAAP net income for 3 months of 2022 was $11.714 million, up 48.3% from $7.899 million in the prior year. Revenue increased 13.4% to $22.699 million from $20.025 million a year earlier.
Source: {source} pictogram news.codiagnostics.com
Pictogram next
25.03.2022
Co-Diagnostics' GAAP net income for 2021 was $36.659 million, down 13.7% from $42.479 million in the prior year. Revenue increased 31.3% to $97.886 million from $74.553 million a year earlier.
Source: {source} pictogram news.codiagnostics.com
Pictogram next
22.12.2021
Co-Diagnostics acquires Idaho Molecular and Advanced Conceptions. Co-Diagnostics is working with these companies to develop a PRC test for COVID-19, YourTest. As payment, Co-Diagnostics will issue 4.72 million shares and 456,000 warrants. The transactions are expected to close by the end of 2021.
Source: {source} pictogram news.codiagnostics.com
Pictogram next
12.11.2021
Co-Diagnostics' GAAP net income for 9M 2021 was $29.16 million, down 1.7% from $29.671 million in the prior year. Revenue increased 63.4% to $77.484 million from $47.408 million a year earlier.
Source: {source} pictogram news.codiagnostics.com
Pictogram next
All Co-Diagnostics news
General information
Company nameCo-Diagnostics
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Life Sciences Tools & Services / Life Sciences Tools & Services
Business address4049 SOUTH HIGHLAND DRIVE SALT LAKE CITY UT 84124 8012789769
Mailing address4049 SOUTH HIGHLAND DRIVE SALT LAKE CITY UT 84124
Websitecodiagnostics.com